Seoul Bio Hub resident company Curebus (CEO Seong-jin Cho) and Samsung Seoul Hospital (Director Seung-woo Park) announced that they have signed a memorandum of understanding (MOU) with the goal of jointly developing a small molecule new drug for the treatment of colon cancer.
This agreement aims to combine the clinical experience and new drug development capabilities of both organizations to secure a treatment alternative for patients with colon cancer who do not respond to immunotherapy.
Professor Yong-Beom Cho's research team at Samsung Medical Center will build an efficacy evaluation system based on clinical infrastructure and patient data for colorectal cancer, verify the efficacy of candidate compounds, and provide clinical consulting. CureVerse will leverage its small molecule compound design and synthesis technology and its experience in new drug development to design, optimize, and provide medicinal chemistry consulting for new candidates.
The two organizations plan to accelerate the development of a treatment for colorectal cancer refractory to immunotherapy through a collaborative system linking non-clinical and clinical trials, and to examine the possibility of expanding indications to various types of cancer in the future based on research results.
Professor Yong-Beom Cho of Samsung Medical Center expressed his anticipation for this collaboration, citing the need for innovative drug discovery to address unmet clinical needs. CureVerse Vice President Jin-Wook Jin emphasized, "This collaborative model combines hospital-based clinical research with a company's new drug development technology," adding, "We will continue our research to provide new treatment opportunities for patients with low responsiveness."
- See more related articles
You must be logged in to post a comment.